ArticleLeukemia research2017
Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia.
Article in Leukemia research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Repurposing artesunate in acute myeloid leukemia: a pharmacokinetic rationale derived from antimalarial data.Cancer chemotherapy and pharmacology · 2026Article
- Artesunate acts through cytochrome c to inhibit growth of pediatric AML cells.Scientific reports · 2023Article
- Progress on the study of the anticancer effects of artesunate.Oncology letters · 2021Review
- Artesunate inhibits melanoma progression in vitro via suppressing STAT3 signaling pathway.Pharmacological reports : PR · 2021Article
- Enhanced lysosomal function is critical for paclitaxel resistance in cancer cells: reversed by artesunate.Acta pharmacologica Sinica · 2021Article
- Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax.Blood advances · 2021Article
- Progress in Redirecting Antiparasitic Drugs for Cancer Treatment.Drug design, development and therapy · 2021Review
- Artemisinin-type drugs for the treatment of hematological malignancies.Cancer chemotherapy and pharmacology · 2021Review
- Drug Repurposing for Targeting Acute Leukemia WithFrontiers in pharmacology · 2021Review
- Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing.Pharmacology & therapeutics · 2020Review
- Research Progress on Artemisinin and Its Derivatives against Hematological Malignancies.Chinese journal of integrative medicine · 2020Review
- Artesunate induces apoptosis and inhibits the proliferation, stemness, and tumorigenesis of leukemia.Annals of translational medicine · 2020Article
- Identification of HRSC advances · 2019Article
- Artesunate and sorafenib: Combinatorial inhibition of liver cancer cell growth.Oncology letters · 2019Article
- Artesunate enhances adriamycin cytotoxicity by inhibiting glycolysis in adriamycin-resistant chronic myeloid leukemia K562/ADR cells.RSC advances · 2019Article
- Artesunate-induced mitophagy alters cellular redox status.Redox biology · 2018Article
- Antitumor Research on Artemisinin and Its Bioactive Derivatives.Natural products and bioprospecting · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
The artimisinins are a class of antimalarial compounds whose antiparasitic activity is mediated by induction of reactive oxygen species (ROS). Herein, we report that among the artimisinins, artesunate (ARTS), an orally bioavailable compound has the most potent antileukemic activity in AML models and primary patients' blasts. ARTS was most cytotoxic to the FLT3-ITD+ AML MV4-11 and MOLM-13 cells (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.